<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a high risk of therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>) in patients receiving oral administration of <z:chebi fb="0" ids="4911">etoposide</z:chebi> for recurrent <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined 119 patients with <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were initially treated with <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, or <z:chebi fb="2" ids="27899">cisplatin</z:chebi> with or without radiation before <z:chebi fb="0" ids="4911">etoposide</z:chebi> treatment </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4911">Etoposide</z:chebi> was used as the final drug in most cases </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-four patients were treated with the oral administration of <z:chebi fb="0" ids="4911">etoposide</z:chebi> (50 or 100 mg/day for 5-7 days at 4-week intervals) </plain></SENT>
<SENT sid="5" pm="."><plain>Three cases of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> developed among those 24 patients exposed to <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, the development of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was not observed in the other 95 patients not treated with <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Our data suggest that there is a substantial risk of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> with oral administration of <z:chebi fb="0" ids="4911">etoposide</z:chebi> for a prolonged period as well as i.v. schedules </plain></SENT>
</text></document>